The main objective of the present work was to investigate, for the first time, the antitumor effect, lipid peroxidation, nitrosative stress and antioxidant status of organic heterocyclic Triazole derivatives.
Method:The antitumor activity of Triazole derivatives was evaluated against Ehrlich ascites carcinoma (EAC) bearing mice as a model for the cancer at doses of 10 and 15 mg/kg body weight, while acute toxicity studies were performed to determine the safety of the compound. Briefly, A total of 105 female Swiss albino mice were divided into 7 groups (n=15), the EAC cells were injected (i.p.) into sixty female mice (in 4 equal groups), and after a one day incubation period, Azole injected with in a dose (10 and 15 mg / kg body wt. day after day). After 10 days, ten animals in each group were sacrificed for observation of antitumor activity and the remaining animals were observed to determine host the life span. Antitumor effect was determined by evaluation of tumor volume, viable tumor cell count of the host, determination of apoptosis-related proteins P53 and Bcl2 levels, Malondialdehyde (MDA), Nitric oxide (NO) and reduced glutathione (GSH) in Liver tissue. The standard antitumor used was cisplatin.Results: Administration of Azole in a dose of 10, 15 mg significantly decreased EAC cells volume and count in a dose-dependent manner. Furthermore, Significant (p < 0.001) decrease in MDA and NO levels Meanwhile GSH was significantly (p < 0.001) increased. P53 highly significantly (p < 0.001) increased while Bcl2 level highly significant (p < 0.001) decreased after treatment with Azole 10, 15 mg. Moreover, injection with Azole 10 and 15 mg highly significantly (p < 0.001) increased AST, ALT and ALP activity.
Conclusion:The results suggest that Azole exhibit significant antitumor activity in Ehrlich ascites carcinoma (EAC) bearing mice that is comparable to that of the reference standard, cisplatin. But, has a hepatorenal toxic effect.